Signs that Amgen was cooling on rocatinlimab emerged last year. Asked about the market positioning of the antibody at a Citi ...

The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...

Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.

Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...

Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings ...

In the latest bunch of recommendations from the European Medicines | Sanofi, Novo Nordisk, UCB and others received positive ...

"EMA will now review all available data to assess whether this emerging information has an impact on the balance of benefits ...

Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds. On January ...

Amgen says its MariTide obesity drug helped patients maintain weight loss for a second year, with good safety and fewer side effects.

Amgen Inc. Buy thesis: strong pipeline, 12% Q3 2025 revenue growth and MariTide obesity upside. Click for this updated look ...

Amgen CEO Bob Bradway discussed his company's weight loss drug in an interview with CNBC's Jim Cramer.

Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, Bernstein ...